Antenatal care now boasts of improvements in awareness about preeclampsia screening. This is a clear market that the market for preeclampsia laboratory testing will witness a progressing trail in long term. It is worthwhile to mention that maternal and foetal mortality caused by undiagnosed and untreated preeclampsia can be prevented. For this reason, awareness remains instrumental to build-up the market.
Furthermore, the number of COVID-19 positive pregnant women is on the rise. Since the developed and developing nations are facing a surge in health-related risks alike, preeclampsia is reported as the third leading cause of maternal mortality in the United States of America alone. It can also be linked with increasing instances of cardiovascular and metabolic diseases in both the mother and the child, later in life. On the basis of these reasons, it can be assumed that preeclampsia laboratory testing market primarily benefits from two factors-a high prevalence of preeclampsia in developing countries, coupled with several product launches to cater to this surging caseload.
The U.S. preeclampsia laboratory testing market will rise at a CAGR of 5.1% during the forecast period of 2021-2026, reaching the market volume of 4,629,000 by 2026.
Data released by National Institutes of Health (NIH) indicates that big investments are made to research preeclampsia. Government and academic institutions are also focusing on building better infrastructure around diagnostics and treating preeclampsia. For instance, DiabetOmics, a U.S. based medical diagnostic company launched a rapid point-of-care testing solution “Lumella”. This test finds the elevation of a protein biomarker that can lead to preeclampsia in pregnant women.
Global Information, Inc. (JASDAQ 4171) www.giiresearch.com Toll Free (US): +1-866-353-3335 Outside US: +1-860-674-8796 Europe (Belgium): +32-2-535-7543 Email: email@example.com
Global Information, Inc. (JASDAQ 4171)
Toll Free (US): +1-866-353-3335
Outside US: +1-860-674-8796
Europe (Belgium): +32-2-535-7543